Bernstein says Bitcoin’s downturn lacks systemic failures and keeps its long-term price target at $150,000 despite weak market sentiment. Bernstein has reiteratedBernstein says Bitcoin’s downturn lacks systemic failures and keeps its long-term price target at $150,000 despite weak market sentiment. Bernstein has reiterated

Bernstein predicts Bitcoin rebound to 150k despite lingering bear worries

2026/02/10 14:30
3 min read

Bernstein says Bitcoin’s downturn lacks systemic failures and keeps its long-term price target at $150,000 despite weak market sentiment.

Bernstein has reiterated its bullish stance on Bitcoin despite ongoing market weakness. The firm said the current downturn does not resemble past crisis-driven cycles.

Analysts maintained their long-term $150,000 target while describing recent losses as confidence-driven rather than structural.

Bernstein says current Bitcoin sell-off lacks past cycle failures

Bernstein analysts said the present Bitcoin bear phase shows no signs of systemic breakdown.

Previous downturns were driven by major failures such as Mt. Gox, Terra-Luna, and FTX. The firm said no similar events have appeared in the current cycle.

The analysts stated that Bitcoin’s network continues operating without disruption. They noted there have been no widespread insolvencies or liquidity freezes.

Hidden leverage has also not surfaced during this phase.

In a client note, the Bernstein team led by Gautam Chhugani said the weakness reflects sentiment pressure. They said the underlying investment thesis remains intact.

The firm reiterated its long-term Bitcoin price target of $150,000.

Institutional alignment and ETF structure support long-term outlook

Bernstein identified stronger institutional alignment as a key difference in this cycle. The firm cited the approval and rollout of U.S. spot Bitcoin ETFs.

Analysts said these products provide regulated access despite muted inflows.

They explained that tight financial conditions have limited risk asset demand. However, they said ETF infrastructure remains functional and ready for capital.

Bernstein expects inflows to increase as liquidity conditions ease. The analysts added that institutional products reduce operational and custody risks.

They said this structure offers stability during periods of volatility. The presence of regulated channels was described as a supportive factor for Bitcoin.

Related Reading: Bitcoin Ranges After 20% Bounce as Key Liquidity Levels Shape Market Direction

Liquidity conditions and balance sheets shape downside risks

Bernstein said Bitcoin continues to trade as a liquidity-sensitive asset.

Analysts noted Bitcoin has lagged gold during periods of tight money. They attributed this trend to higher interest rates and reduced global liquidity.

The firm also addressed concerns tied to artificial intelligence and digital systems. Analysts said blockchains remain central to programmable finance.

They described Bitcoin as suitable for global machine-readable transactions.

Bernstein noted that large Bitcoin holders have structured liabilities for prolonged downturns.

Strategy CEO Phong Le said restructuring would only occur if Bitcoin stayed at $8,000 for five years.

The firm also said miner risks are lower due to diversification into AI-related energy demand.

The post Bernstein predicts Bitcoin rebound to 150k despite lingering bear worries appeared first on Live Bitcoin News.

Market Opportunity
Belong Logo
Belong Price(LONG)
$0.002409
$0.002409$0.002409
-2.46%
USD
Belong (LONG) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26